Trial · NCT03744663

Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films

NCT03744663, Phase 2, Withdrawn, Wake Forest University Health Sciences

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films. Trials, record NCT03744663. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03744663

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films
NCT number: NCT03744663
Status: Withdrawn
Phases: Phase 2
Enrollment: 0 participants, actual
Lead sponsor: Wake Forest University Health Sciences
Conditions: Opioid Use
Interventions: Suboxone® SL, Sublocade®
First posted: 2018-11-16
Last updated: 2022-06-06

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Weeks patients continued in treatment during trial period	26 weeks	Retention in weeks
Primary	Number of Participants that Dropout during the first 28 days of Treatment	first 28 days	Number of participants that leave the study
Primary	Number of participants that complete of the treatment phase	26 weeks	Number of participants that complete the study
Primary	Number of participants who did not complete the trial in their assigned group	26 weeks	Total number of participants that changed arms
Primary	Percentage of negative urinary drug screens	26 weeks	percentage of participants that have a negative drug screen
Primary	Liver enzyme values - ALP, AST, ALT	26 weeks	Values of liver enzymes will be measured: Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT). Values will be reported in IU/L
Primary	Liver enzyme values- Total Bilirubin	26 weeks	Values of liver enzymes will be measured: Total Bilirubin. Values will be reported in mg/dL
Primary	Clinical Opiate Withdrawal Scale (COWS) scores trends	26 weeks	Withdrawal symptoms scale- total score 0-48 with a lower score denoting no symptoms (better Outcomes) and higher score denoting more withdrawal symptoms
Primary	Subjective Opiate Withdrawal Scale (SOWS) score trends	26 weeks	Participant survey for how they are feeling during withdrawal period, score range from 0 to 64. Low score denotes no/less perceived symptoms (better outcomes) and higher score denotes high/ more personal perceived symptoms.
Primary	Number or patients still in medication assisted therapy (MAT) clinic 6 months after trial period ends.	6 months	Number of patients still in MAT clinics at 6 months

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers16

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
11015800	BACKGROUND	PubMed
11058673	BACKGROUND	PubMed
12606177	BACKGROUND	PubMed
16186090	BACKGROUND	PubMed
21466501	BACKGROUND	PubMed
23961726	BACKGROUND	PubMed
24500948	BACKGROUND	PubMed
25583888	BACKGROUND	PubMed
25950251	BACKGROUND	PubMed
26066931	BACKGROUND	PubMed

1 to 10 of 16

See all 16 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03744663

GET https://conductscience.org/api/trials/v1/NCT03744663/registered

API reference For AI assistants